The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale

Haematologica

Volumn 99, Issue 6, 2014, Pages 1107-1113

  Gallamini, Andrea ^a   Barrington, Sally F ^b   Biggi, Alberto ^c   Chauvie, Stephane ^c   Kostakoglu, Lale ^d   Gregianin, Michele ^e   Meignan, Michel ^f   Mikhaeel, George N ^b   Loft, Annika ^g   Zaucha, Jan M ^h   Seymour, John F ^i,j   Hofman, Michael S ⁱ   Rigacci, Luigi ^k   Pulsoni, Alessandro ^l   Coleman, Morton ^m   Dann, Eldad J ⁿ   Trentin, Livio ^o   Casasnovas, Olivier ^p   Rusconi, Chiara ^q   Brice, Pauline ^r   Bolis, Silvia ^s   Viviani, Simonetta ^t   Salvi, Flavia ^u   Luminari, Stefano ^v   Hutchings, Martin ^g   more..

^a CENTRE ANTOINE LACASSAGNE   (France)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d MOUNT SINAI MEDICAL CENTER   (United States)

^e VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^f Hôpitaux universitaires Henri Mondor   (France)

^g Rigshospitalet   (Denmark)

^h UNIVERSITY OF GDA SK   (Poland)

ⁱ PETER MACCALLUM CANCER CENTRE   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k UNIVERSITY OF FLORENCE   (Italy)

^l SAPIENZA UNIVERSITY OF ROME   (Italy)

^m WEILL CORNELL MEDICAL COLLEGE   (United States)

ⁿ RAMBAM MEDICAL CENTER   (Israel)

^o UNIVERSITY OF PADOVA   (Italy)

^p HÔPITAL DU BOCAGE   (France)

^q OSPEDALE NIGUARDA CA GRANDA   (Italy)

^r SAINT LOUIS HOSPITAL   (France)

^s Department of Dermatology   (Italy)

^t NATIONAL CANCER INSTITUTE   (Italy)

^u C Arrigo Children's Hospital   (Italy)

^v UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; DACARBAZINE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; VINBLASTINE;

ADOLESCENT; ADULT; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER STAGING; DEAUVILLE FIVE POINT SCALE; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DISEASE COURSE; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HODGKIN DISEASE; HUMAN; INTERNATIONAL PROGNOSTIC SCORING SYSTEM; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OBSERVER VARIATION; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PREDICTIVE VALUE; PROGRESSION FREE SURVIVAL; RATING SCALE; REPRODUCIBILITY; RETROSPECTIVE STUDY; SENSITIVITY AND SPECIFICITY; TREATMENT FAILURE; TREATMENT OUTCOME; DIAGNOSTIC USE; MIDDLE AGED; MORTALITY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FLUORODEOXYGLUCOSE F18; FOLLOW-UP STUDIES; HODGKIN DISEASE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; PROGNOSIS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84901711760     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2013.103218     Document Type: Article

References (46)

1. Seam P, Juweid ME, Cheson BD. The role of FDG-PET scans in patients with lymphoma. Blood. 2007;110(10):3507-16.
2. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an International Workshop to standardize response criteria for non-Hodgkin's lymphomas. J Clin Oncol. 1999;17(4):1244-53.
3. Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC. 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica. 2006;91(4):522-9.
4. Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, et al. FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood. 2006;107(1):52-9.
5. Gallamini A, Rigacci L, Merli F, Nassi L, Bosi A, Capodanno I, et al. The predictive value of positron emission tomography scanning performed after two courses of standard therapy on treatment outcome in advanced stage Hodgkin's disease. Haematologica. 2006;91(4):475-81.
6. Haioun C, Itti E, Rahmouni A, Rain JD, Belhadi K, Gaulard P, et al. [18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. Blood. 2005;106(4):1376-81.
7. Itti E, Juweid ME, Haioun C, Yeddes I, Hamza-Maaloul F, El Bez I, et al. Improvement of early 18F-FDG PET interpretation in diffuse large B-cell lymphoma: importance of the reference background. J Nucl Med. 2010;51(12):1857-62.
8. Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, et al. Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study. J Clin Oncol. 2007;25(24):3746-52.
9. Hutchings M, Mikhaeel NG, Fields PA, Nunan T, Timothy AR. Prognostic value of interim FDG-PET after two or three cycles of chemotherapy in Hodgkin lymphoma. Annals Oncol. 2005;16(7):1160-8.
10. Terasawa T, Lau J, Bardet S, Couturier O, Hotta T, Hutchings M, et al. Fluorine-18-fluorodeoxyglucose positron emission tomography for interim response assessment of advanced-stage Hodgkin's lymphoma and diffuse large B-cell lymphoma: a systematic review. J Clin Oncol. 2009;27(11):1906-14.
11. Meignan M, Gallamini A, Haioun C. Report on the first international workshop on interim-PET scan in lymphoma. Leuk Lymphoma. 2009;50(8):1257-60.
12. Barrington SF, Qian W, Somer EJ, Franceschetto A, Bagni B, Brun E, et al. Concordance between four European Centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma. Eur J Nucl Med Mol Imaging. 2010;37(10):1824-33.
13. Lister TA, Crowther D, Sutcliffe SB, Glatstein E, Canellos GP, Young RC, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol. 1989;7(11):1630-6.
14. Hasenclever D, Deihl V. A prognostic score for advanced Hodgkin's disease. N Engl J Med. 1998;339(21):1506-14.
15. Chauvie S, Stancu A, Cerello P, Biggi A, Gallamini A. A clinical trial toolkit for diagnostic imaging exchange through the WEB [abstract]. Proceedings of 22nd Annual EANM Meeting 2009; Barcelona, Spain: Eur J Nucl Med Mol Imaging. 2009; 36 (Suppl 2) Abstract P-234.
16. Meignan M, Itti E, Bardet S, Lumbroso J, Edeline V, Olivier P, et al. Development and application of a real-time on-line blinded independent central review of interim PET scans to determine treatment allocation in lymphoma trials. J Clin Oncol. 2009;27(16): 2739-41.
17. Meignan M, Gallamini A, Haioun C, Polliack A. Report of the Second International Workshop on interim positron emission tomography in lymphoma held in Menton, France, 8-9 April 2010. Leuk. Lymphoma. 2010;51(12):2171-80.
18. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53,457-81.
19. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep. 1966;50(3):163-70.
20. Cox DR. Regression models and life tables. Journal of the Royal Statistical Society: Series B (Statistical Methodology), 1972;34, 187-220.
21. Landau S, Everitt BS. A Handbook of Statistical Analyses Using SPSS. Chapman & Hall/CRC 2004, Boca Raton, FL.
22. Reed JF 3rd. Homogeneity of kappa statistics in multiple samples. Comput. Methods Programs Biomed. 2000;63(1):43-6.
23. Viviani S, Bonadonna G, Santoro A, Bonfante V, Zanini M, Devizzi L, et al. Alternating versus hybrid MOPP and ABVD combinations in advanced Hodgkin's disease, ten year results. J Clin Oncol. 1996, 14(5):1421-30.
24. Biggi A, Gallamini A, Chauvie S, Hutchings M, Kostakoglu L, Gregianin M, et al. International validation study for interim PET in ABVD-treated, advanced-stage Hodgkin lymphoma: interpretation criteria and concordance rate among reviewers. J Nucl Med. 2013;54(5):683-90.
25. Cerci JJ, Pracchia LF, Linardi CC, Pitella FA, Delbeke D, Izaki M, et al. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med. 2010;51(9):1337-43.
26. Zinzani PL, Rigacci L, Stefoni V, Broccoli A, Puccini B, Castagnoli A, et al. Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients. Eur J Nucl Med Mol Imaging. 2012;39(1):4-12.
27. Kostakoglu L, Goldsmith SJ, Leonard JP, Christos P, Furman RR, Atasever T, et al. FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease. Cancer. 2006;107 (11):2678-87.
28. Fludeoxyglucose F 18 PET scan-guided therapy or standard therapy in treating patients with previously untreated stage I or II Hodgkin's lymphoma (EORTC/GELA). ClinicalTrials. gov registration number: NCT00433433.
29. HD16 for early stage Hodgkin lymphoma. ClinicalTrials. gov registration number: NCT00736320.
30. Response-based therapy assessed by PET scan in treating patients with bulky stage I and stage II classical Hodgkin lymphoma (CALGB 50801). ClinicalTrials. gov registration number: NCT01118026.
31. Chemotherapy based on PET scan in treating patients with stage I or stage II Hodgkin lymphoma (ECOG). ClinicalTrials. gov registration number: NCT01390584.
32. Chemotherapy based on positron emission tomography scan in treating patients with stage I or stage II Hodgkin lymphoma (CALGB 50604). ClinicalTrials. gov registration number: NCT01132807.
33. Tailored therapy for Hodgkin lymphoma using early interim therapy PET for therapy decision. ClinicalTrials. gov registration number: NCT00392314.
34. Study of a treatment driven by early PET response to a treatment not monitored by early PET in patients with AA stage 3-4 or 2B HL (AHL 2011). ClinicalTrials. gov registration number: NCT01358747.
35. Positron emission tomography (PET)-adapted chemotherapy in advanced Hodgkin lymphoma (HL) (HD0607). ClinicalTrials. gov registration number: NCT00795613.
36. Fludeoxyglucose F 18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma (RATHL). ClinicalTrials. gov registration number: NCT00678327.
37. Fludeoxyglucose F 18-PET/CT imaging and combination chemotherapy with or without additional chemotherapy and G-CSF in treating patients with stage III or stage IV Hodgkin lymphoma (SWOG-CALG-B). ClinicalTrials. gov registration number: NCT00822120.
38. High-Dose chemotherapy and stem cell transplantation, in patients PET-2 positive, after 2 courses of ABVD (HD0801) and comparison of RT versus no RT in PET-2 negative patients (HD0802). ClinicalTrials. gov registration number: NCT00784537.
39. HD17 for intermediate stage Hodgkin lymphoma. ClinicalTrials. gov registration number: NCT01356680.
40. Boellaard R, O'Doherty MJ, Weber WA, Mottaghy FM, Lonsdale MN, Stroobants SG, et al. FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0. Eur J Nucl Med Mol Imaging. 2010;37(1):181-200.
41. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, Lammertsma AA, et al. Consensus recommendations for the use of 18F-FDG PET as an indicator of therapeutic response in patients in National Cancer Institute trials. J Nucl Med. 2006;47(6):1059-66.
42. Zinzani PL, Tani M, Fanti S, Alinari L, Musuraca G, Marchi E et al. Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. Ann Oncol. 2006;17(8): 1296-300.
43. Gallamini A, Fiore F, Sorasio R, Meignan M. Interim positron emission tomography scan in Hodgkin lymphoma: definitions, interpretation rules, and clinical validation. Leuk Lymphoma 2009;50(11):1761-4.
44. Barringtom SF, O'Doherty MJ, Roberts TH, Kirkwood A, Viney ZN, Franceschetto A et al. PET-CT for staging and early response-results from the response adapted therapy in advanced Hodgkin lymphoma (RATHL) study. Haematol Oncol. 2013;31,101 [abstract 018].
45. Gallamini A, Rossi A, Patti C, Picardi M, Di Raimondo F, Cantonetti M, et al. Early treatment intensification in advanced-stage highrisk Hodgkin lymphoma (HL) patients, with a positive FDG-PET scan after two ABVD courses-first interim analysis of the GITIL/FIL HD0607 clinical trial. Blood. 2012;120:[Abstract 550].
46. Press OW, Le Blanc M, Rimsza LM, Schoder H, Friedberg JW, Evans AM, et al. A phase II trial of response-adapted therapy of stages III-IV Hodgkin lymphoma using early interim FDG-PET imaging: US intergroup S0816. Haematol Oncol. 2013;31,137 [abstract 124].